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Herpes simplex virus type 1 gL lacks a transmembrane domain but stably associates with membranes through its
oligomerization with the integral membrane glycoprotein designated gH. The gH-gL oligomers are essential for virion
infectivity and virus-induced cell fusion. Monoclonal and polyclonal antibodies were raised against HSV-1(KOS) gL as probes
for antigenic structure and functional protein domains. Antigenic determinants recognized by these antibodies were found
to be present on gL expressed by many, but not all, strains of HSV-1 and were not detected on gL expressed by HSV-2
strains. These antigenic determinants were localized to the C-terminal region of HSV-1 gL, where amino acid substitutions
define at least two classes of HSV-1 gL and where the sequences of HSV-1 and HSV-2 gL diverge considerably. The
antibodies were extremely effective at inhibiting virus-induced cell fusion, provided the virus strain expressed the relevant
antigenic determinants, but failed to neutralize viral infectivity despite demonstrable binding to virions. These results define
strain-dependent differences in the structure and antigenic conformation of HSV-1 forms of gL and suggest that the roles
of gL in cell fusion and viral entry are different. q 1996 Academic Press, Inc.
INTRODUCTION tivity and for HSV-induced cell fusion. A subset of these
glycoproteins, including gB, gD, gH, and gL, may directly
Herpes simplex virus (HSV) can spread in infected mediate the membrane fusion events required both for
persons via infectious virions or by virus-induced syncy- HSV-1 entry of cells and for HSV-1-induced cell fusion.
tium formation, which is one means of direct cell-to-cell This hypothesis is based on findings that deletion of any
transmission of infection. Although virus-associated syn- one of these four glycoproteins results in mutant virions
cytia are readily observed in herpetic lesions, syncytium that can bind to cells but fail to penetrate (Cai et al.,
formation is not usually apparent after the infection of 1988; Ligas and Johnson, 1988; Forrester et al., 1992;
cultured cells with wild-type virus. Syncytium-forming Roop et al., 1993) and also results in inability of double
(Syn) mutants emerge frequently in cell culture. For HSV mutants (carrying both the glycoprotein deletion and a
type 1 (HSV-1) strains at least, the Syn phenotype can Syn allele) to induce cell fusion (Cai et al., 1988; Ligas
result from nonlethal mutations in any one of several and Johnson, 1988; Davis-Poynter et al., 1994; Novotny
genes, including deletions within the UL20 or UL24 and Spear, manuscript in preparation). Also, antibodies
genes or amino acid substitutions in gK or in the cyto- specific for gB, gD, and gH have been shown to neutral-
plasmic tail of gB (reviewed in Spear, 1993). None of ize viral infectivity by blocking viral entry, but not binding
these mutations has been shown to alter virion infectivity (Fuller and Spear, 1987; Highlander et al., 1987, 1988;
and it is not known how they influence cell fusion. For Fuller et al., 1989), and to inhibit HSV-induced cell fusion
most HSV-1 Syn mutants, including the ones used here,
(Noble et al., 1983; Minson et al., 1986; Gompels and
cell fusion depends on the expression of viral proteins
Minson, 1986; Sanchez-Pescador et al., 1993).
by the infected cells (fusion-from-within), although some
Other HSV-1 glycoproteins influence viral infectivity orHSV-1 Syn mutants can induce fusion through the action
cell fusion but may not have a direct role in membraneof virions bridging two cells (fusion-from-without) (Walev
fusion. For example, deletion of the HSV-1 gene encodinget al., 1991b, 1991a). Use of Syn mutants for the investiga-
gC reduces infectivity by reducing the binding of virus totion of molecular requirements for viral entry and cell
cells (Herold et al., 1991, 1994) but does not inhibit virus-fusion permits assessment of the mechanistic similari-
induced cell fusion. In fact, many Syn mutants are gC-ties and differences in the two processes.
negative (Heine et al., 1974; Zezulak and Spear, 1984)Multiple viral glycoproteins are required for HSV infec-
and it has been suggested that, in cultured cells, the
Syn phenotype and expression of gC may be somewhat
incompatible (Zezulak and Spear, 1984; Spear, 1993).1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (312) 503-1339. E-mail: p-spear@nwu.edu. Conversely, deletions of HSV-1 genes encoding gE, gI,
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or gM can reduce the efficiency of virus-induced cell those of HSV gH and gL have been identified in diverse
animal and human herpesviruses (Gompels and Minson,fusion (Davis-Poynter et al., 1994) but appear to be with-
out effect on virion infectivity in the case of gE or gI 1986; Gompels et al., 1988; Klupp and Mettenleiter, 1991;
Kaye et al., 1992; Yaswen et al., 1993; Liu et al., 1993;(Longnecker and Roizman, 1987; Neidhardt et al., 1987;
Schranz et al., 1989) or reduce the yields of infectious Forghani and Grose, 1994; Klupp et al., 1994). Although
the primary amino acid sequences are not well-con-virus by no more than 10-fold in the case of gM (MacLean
et al., 1991; Baines and Roizman, 1991). Finally, deletion served, the oligomerization of gH-gL homologs and re-
quirement of the oligomers for viral infectivity appears toof the HSV-1 UL45 gene eliminates the ability of a Syn
mutant to induce cell fusion (Haanes et al., 1994) but is be constant for diverse herpesviruses.
Antibodies specific for HSV-1(KOS) gL were producedwithout effect on viral infectivity (Visalli and Brandt, 1991).
In the case of varicella-zoster virus (VZV), which like to use as probes for epitopes of gL and as potential
inhibitors of gL function in infectivity and cell fusion. Poly-HSV-1 and HSV-2 belongs to the alphaherpesvirus sub-
family, expression of gH and gL in a vaccinia virus ex- clonal and monoclonal anti-gL antibodies reacted with
gL expressed by some, but not all, strains of HSV-1 andpression system results in cell fusion (Duus et al., 1995).
It is not clear why these two VZV proteins alone (or per- failed to react with gL expressed by all HSV-2 strains
tested. Nucleotide sequence analysis revealed that vari-haps in conjunction with vaccinia proteins) can induce
cell fusion when the requirements seem to be much more ations in amino acid sequence in the C-terminal half of
gL define at least two subtypes of HSV-1 gL, only one ofcomplex for HSV-1. Attempts to achieve HSV-1-induced
cell fusion by expression of gH and gL together or by which reacts with HSV-1(KOS)-specific antibodies. Use
of hybrid forms of gL in Western blots permitted the map-expression of various combinations of these and other
glycoproteins implicated in cell fusion have not suc- ping of important variable epitopes of HSV-1 gL to the
C-terminal quarter of the molecule. Antibodies specificceeded (Spear, 1993; Davis-Poynter et al., 1994; T. Terry-
Allison, M. J. Novotny, and P. G. Spear, unpublished stud- for these epitopes were potent inhibitors of cell fusion
induced by appropriate HSV-1 strains but failed to neu-ies). It seems likely that the HSV-1 proteins required for
cell fusion will include at least gB, gD, gH, and gL as the tralize viral infectivity, suggesting that gL may participate
in different ways in the two processes, perhaps moreputative fusogenic proteins. Other HSV-1 proteins may
influence the transport or function of the mediators of directly in cell fusion.
fusion or may induce the cytoplasmic reorganization as-
sociated with syncytium formation. MATERIALS AND METHODS
The focus of this study is gL and its role in viral infectiv-
Cells and viruses
ity and cell fusion. HSV-1 gL was shown previously to
associate stably with gH to form hetero-oligomers Human HEp-2 cells and African green monkey kidney
(Vero) cells were obtained from the American Type Cul-(Hutchinson et al., 1992). In the absence of gL, gH re-
mains associated with the endoplasmic reticulum in an ture Collection. HEp-2 cells were grown in Dulbecco’s
modified Eagle medium (DMEM; GIBCO Laboratories)immature form (Foa`-Tomasi et al., 1991; Gompels and
Minson, 1989; Roberts et al., 1991), whereas hetero- supplemented with 10% fetal bovine serum (FBS; Sigma
Chemicals). Vero cells were grown in medium 199 (199;oligomerization with gL permits transport of gH to the
cell surface and the associated processing of its glycans GIBCO Laboratories) supplemented with 5% FBS. F6
cells, a cell line derived from Vero and able to supply(Hutchinson et al., 1992). This hetero-oligomer is thought
to be the functional unit required for virion infectivity HSV-1 gH in trans (Forrester et al., 1992), were obtained
from A. C. Minson (University of Cambridge, Cambridge,(Roop et al., 1993) and also for virus-induced cell fusion
(Davis-Poynter et al., 1994; Novotny and Spear, manu- UK) and were maintained in DMEM supplemented with
10% FBS and Geneticin (GIBCO Laboratories) at 400 mg/script in preparation). On the basis of amino acid se-
quence (McGeoch et al., 1988), in vitro translation experi- ml. All cells were plated in medium 199 supplemented
with 1% heat-inactivated FBS (199V) prior to infection. Allments (Novotny and Spear, manuscript in preparation),
and expression from eukaryotic vectors (Novotny and infections were performed by exposing cell monolayers
to a minimal volume of virus diluted in phosphate-buf-Spear, 1993, Abstract for the XVIII International Herpesvi-
rus Workshop; Dubin and Jiang, 1995), it appears that gL fered saline (PBS) containing 0.1% (wt/vol) glucose and
1% heat-inactivated FBS (PBS-G-CS). After a 2-hr adsorp-is not an integral membrane glycoprotein but is made as
a potentially secreted glycoprotein that becomes tightly tion period with rocking, the virus inocula were removed
and replaced with 199V or, in the case of plaque assays,associated with membranes through its interaction with
gH. Both serotypes of HSV (HSV-1 and HSV-2) express 199V containing 0.1% human g-globulin or 0.5% methyl
cellulose. The following viral strains were used: HSV-2gL. Nucleotide sequences determined for one HSV-1
strain and one HSV-2 strain indicate 65% identity and 75% strains G (Ejercito et al., 1968), 333, and HG52; HSV-1
strains KOS, KOS(804) (Little and Schaffer, 1981), MPoverall similarity in amino acid sequences (McGeoch et
al., 1988, 1991). Glycoproteins with properties similar to (Hoggan and Roizman, 1959), ANG (Munk and Ludwig,
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1972), HFEM(syn) (Baucke and Spear, 1979), Patton, F containing an amino-terminal histidine hexamer se-
quence fused to amino acids 34–169 of gL, which are(Ejercito et al., 1968), 17, Noble (a clinical isolate), FR (a
plaque isolate of F), 14-012, Cl101, and VR3. Virus stocks in turn fused via a two amino acid spacer to an 11 amino
acid epitope from influenza virus hemagglutinin (Flu epi-were prepared by low-multiplicity passage in HEp-2 cells
and their titers determined on Vero cells. HSV- tope) and was constructed by inserting the XhoI/XbaI
fragment of pMN115 (XbaI end filled in) between the1(SC16)SCgHZ, a gH-negative HSV-1 mutant (Forrester
et al., 1992) obtained from A. C. Minson, was propagated XhoI and HindIII sites (HindIII end filled in) of pTrcHis-
C. pMN115, to be described in detail later (Novotny andand assayed in F6 cells.
Spear, manuscript in preparation), has the CMV promoter
linked to gL amino acids 1–169 fused to the Flu epitope.Plasmids
Plasmid pMN102 encodes a 10.6-kDa hybrid protein
[His-gL(168–224)] containing an amino terminal histidineSeveral plasmids, each containing the UL1 (gL) open
reading frame from a different HSV-1 strain, were con- hexamer sequence fused to amino acids 168–224 of gL
and was constructed by inserting the appropriatestructed [pMN49 from HSV-1(KOS); pMN53 from HSV-
1(KOS)804; pMN80 from HSV-1(SC16)SCgHZ; pMN81 Eco0109I/NcoI fragment of the PCR product between the
BglII and EcoRI sites of pTrcHis-C, by blunt-end ligationfrom HSV-1(HFEM)syn]. The inserts were obtained by
polymerase chain reaction (PCR), digested with BamHI after filling in all sticky ends. Figure 1 presents diagrams
of the hybrid proteins expressed by these plasmids. All(a site introduced by the upstream primer) and XbaI or
EagI (sites found downstream of the UL1 open reading primers used for PCR and sequencing were obtained
from the Northwestern University Biotechnology Center.frame) and inserted between the BamHI and XbaI or
HincII sites of pGEM3 (Promega). PCR was carried out
using Vent DNA polymerase (New England Biolabs), the Polyclonal and monoclonal antibodies specific for gL
appropriate viral genomic DNA as template, and primers and other proteins
based on the published sequence (McGeoch et al., 1988)
of HSV-1(17). Appropriate nucleotide substitutions in the Hybrid proteins depicted in Fig. 1 were purified for use
as immunogens and as antigens for detection of specificprimer sequences introduced a BamHI site in the up-
stream primer [5*-TGGGTGCgGAtCCTAGGCGC-3*, cor- antibodies. The hybrid proteins were produced in bacte-
ria induced with IPTG and were isolated from inclusionresponding to nucleotides 9318 to 9337 on the HSV-1(17)
genome] and an EcoRI site in the downstream primer bodies as described in Current Protocols in Molecular
Biology, chapter 16.5. Purified GST-gL(34–224) was pre-[5*-AGAGGGAAtTCCCTCTCCC-3*, complementary to
nucleotides 11024 to 11006 on the HSV-1(17) genome]. pared by electroelution of the protein from preparative
SDS–polyacrylamide gels and extraction with methanol/Nucleotide sequences were determined for the gL open
reading frames (both strands) in all these plasmids and acetone (1:1). The His-gL hybrid proteins were purified
by metal-chelate affinity chromatography on a nickel-in derivatives of these plasmids from which N-terminal
or C-terminal regions of the inserts were deleted, using charged ProBond resin under denaturing conditions ac-
cording to the manufacturer’s protocol (Invitrogen). Forthe dideoxynucleotide chain termination method (Seque-
nase kit Version 2.0, United States Biochemicals) and T7 the production of polyclonal antibodies, rabbits were im-
munized with purified GST-gL(34–224) [100 mg per rabbitand Sp6 primers. Other plasmids capable of expressing
gL hybrid proteins in prokaryotic systems were con- in Hunter’s Titer Max (CytRx Corp.) injected subcutane-
ously at multiple sites, followed by boosts at 1-monthstructed. The inserts for these plasmids were obtained
by enzymatic digestions of HSV-1(KOS) DNA-containing intervals with the same amount of protein in Freund’s
incomplete adjuvant] or with an adenovirus vector ex-plasmids described above or of the PCR product ob-
tained as described above, using HSV-1(KOS) DNA tem- pressing full-length HSV-1(KOS) gL (Hutchinson et al.,
1992), which was obtained from D. C. Johnson (McMasterplate. Plasmid pMN60 encodes a 46-kDa hybrid protein
[GST-gL(34–224)] containing amino acids 34–224 of gL University, Hamilton, Ontario, Canada) and purified by
cesium chloride gradient centrifugation. The rabbit anti-fused to the carboxyl teminus of glutathione-S-trans-
ferase and was constructed by inserting the appropriate sera used in this study are designated R88 [raised
against GST-gL(34–224)] and R89 (raised against theXhoI fragment from the PCR product, after filling in the
ends, into the SmaI site of pGEX-2T (Pharmacia LKB). gL-expressing adenovirus vector). For the production of
mouse monoclonal antibodies (mAbs), Balb/c mice werePlasmid pMN62 encodes a 25.1-kDa hybrid protein [His-
gL(34-224)] containing an amino-terminal histidine hex- immunized with the GST-gL(34–224) hybrid protein in
Hunter’s TiterMax by injection subcutaneously at severalamer sequence fused to amino acids 34–224 of gL and
was constructed by inserting the appropriate XhoI/HindIII sites. This immunization was repeated once with adju-
vant at 43 days. The final injection 3 days prior to sacrificefragment of plasmid pMN49 between the XhoI and HindIII
sites of pTrcHis-C (Invitrogen). Plasmid pMN117 en- of the mice was without adjuvant and by intravenous
route. The spleen cells from two immunized mice werecodes a 21.3-kDa hybrid protein [His-gL(34–169)Flu]
AID VY 7987 / 6a19$$$222 05-30-96 03:12:22 vira AP: Virology
4 NOVOTNY, PARISH, AND SPEAR
pooled for fusion with Sp2/0-Ag14 cells using polyethyl- with chemiluminescent ECL reagent (Amersham) for 30
sec prior to exposure to Amersham Hyperfilm-MP.ene glycol (3000–3700 centipoise; Sigma Chemicals)
and the ‘‘fusion by stirring’’ method as described (Harlow
Antibody binding to HSV-1 virionsand Lane, 1988). Culture media of hybrid clones obtained
by HAT selection were screened for the presence of
HSV-1 virions were purified on dextran gradients (Cas-
anti-gL antibodies by dot blot assays. The first assay
sai et al., 1975) for use in ELISA or immunoprecipitation
identified antibodies capable of binding to the His-gL(34–
experiments. For ELISA, virions were diluted 1:50 or 1:100
224) hybrid protein and the second identified antibodies
in 50 mM sodium phosphate buffer, pH 6.1, and dis-
capable of binding to antigens present in octylglucoside
pensed into 96-well plates (Dynatech Immulon) at 107
lysates of HSV-1(KOS)-infected HEp-2 cells but not in
PFU in 100 ml per well. Adsorption of virions to the plates
lysates of uninfected HEp-2 cells. The antigens used for
occurred at 47 overnight. The plates were washed with
these screens were immobilized on nitrocellulose in a
0.05% Tween 20 in PBS (TPBS) and remaining binding
96-well manifold. The detection system was horseradish
sites blocked at room temperature with 3% bovine serum
peroxidase-coupled protein A and 3,3*diaminobenzidine
albumin in TPBS (BSA-TPBS). The concentrations of
tetrahydrochloride as substrate (Sigma) for the first
mouse IgG present in hybridoma culture supernatants
screen and ECL substrate (Amersham) for the second
were determined by ELISA. The culture supernatants,
screen. Five hybridomas producing anti-gL mAbs (VIII-
diluted with BSA-TPBS to contain an appropriate range
62, VIII-82, VIII-87, VIII-200, and VIII-820) were obtained.
of concentrations of mAb, were then added to each well
Rabbit antisera specific for HSV-1 gH (R83) or VP5 (anti-
and incubated at room temperature for 1 hr. The plates
NC1) (Cohen et al., 1980) were obtained from R. Eisen-
were washed with TPBS before the addition of horserad-
berg and G. Cohen (University of Pennsylvania, Philadel-
ish peroxidase-conjugated goat anti-mouse IgG (Fc spe-
phia, PA). MAbs specific for various HSV glycoproteins
cific; Sigma Chemicals) diluted 1:5000 in BSA-TPBS. After
(II-105, III-114, III-174, III-252, and 52S) have been de-
1 hr at room temperature and five washes with TPBS,
scribed elsewhere (Showalter et al., 1981; Para et al.,
the substrate orthophenylenediamine (Sigma Chemicals)
1985). A mAb specific for HSV-1 gC (VII-13-7) was pro-
was added. The reaction was stopped after 10 to 20 min
duced earlier by methods similar to those described here
by the addition of 4 M H2SO4 and the OD490 was read(Parish and Spear, unpublished studies). A mAb specific
in a Dynatech Laboratories microtiter plate reader. For
for the Flu epitope (12CA5) (Wilson et al., 1984) is avail-
immunoprecipitation of intact virions, 200 ml of dextran-
able from Boehringer Mannheim.
purified virus was diluted to 0.6 ml with PBS, to which
was added 5 ml of ascites fluid containing approximately
Western blotting 30 mg of anti-gL mAb (VIII-87) or anti-gB mAb (II-105).
Control mixtures were prepared without antibody or with-
Antigens used for Western blots were gL hybrid pro-
out either virus or antibody. The mixtures remained on
teins prepared as described above or lysates prepared
ice for 3 hr. Then 100 ml of a 30% suspension of protein
from infected or uninfected HEp-2 cells or from purified
A agarose was added for an additional 2 hr on ice. The
virions (Cassai et al., 1975). The cells or virions were
agarose beads were washed and bound material was
disrupted with 1% NP-40, 0.5% sodium deoxycholate, 0.1
eluted with SDS sample buffer. The proteins were re-
mM phenylmethylsulfonyl fluoride in 50 mM Tris–HCl
solved on 10% SDS–PAGE and transferred to nitrocellu-
(pH 8.0), and insoluble debris removed from the lysates
lose for Western blotting with the rabbit antiserum (anti-
by centrifugation. The lysates or purified proteins or pre-
NC-1) specific for the major capsid protein VP5.
cipitated virions were mixed with sample buffer for SDS –
PAGE and subjected to electrophoresis on 12–15% poly- Assays of antibody inhibitory activities
acrylamide gels (Bio-Rad Laboratories). The separated
proteins were electrophoretically transferred from the gel Neutralization of HSV-1(KOS) infectivity by mAbs or
rabbit antisera was quantitated as previously describedto nitrocellulose using a Millipore semidry blotter and a
discontinuous buffer system (Towbin et al., 1979). The (Para et al., 1985). To determine the effects of mAbs on
cell fusion induced by syncytial strains of HSV-1 afternitrocellulose blot was incubated with blocking buffer
[150 mM NaCl, 10 mM Tris–HCl (pH 7.4), 5% nonfat milk, high multiplicity infections, Vero cells plated in 24-well
dishes were infected at 20 PFU per cell. After a 2-hr0.2% Tween 20, 0.02% thimerosal] and then with rabbit
serum diluted 1:4000 or mouse ascites fluid diluted adsorption period at 377, the virus inoculum was removed
and the cells were overlaid with 199V containing serial1:4000 in blocking buffer. The blots were then incubated
with purified horseradish peroxidase-coupled goat anti- dilutions of ascites fluids, which had previously been
heated to 567 for 30 min to inactivate complement. Therabbit or goat anti-mouse antibodies diluted 1:5000 in
blocking buffer. Washes with 150 mM NaCl, 10 mM Tris – concentrations of mouse IgG in the ascites fluids were
determined by ELISA. After incubation for 18 to 24 hr,HCl (pH 7.4), 0.2% Tween 20 were performed after each
incubation with antibodies. Detection was by incubation the cells were washed with PBS, fixed with methanol,
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FIG. 1. Diagram of the gL polypeptide and of prokaryotic hybrid proteins expressed by plasmids used in this study. pMN49 contains the entire
open reading frame for HSV-1(KOS)gL. Positions of the putative signal peptide sequence (cross-hatched box) and of the site for addition of N-linked
carbohydrate (black box designated N-Cho) are indicated. Also shown are the positions of the sites for the restriction endonucleases, XhoI (X) and
Eco0109I (E), which were used to assemble the hybrid open reading frames. pMN60 encodes a hybrid protein comprising the 26-kDa glutathione
S-transferase (leftward diagonal hatch) fused to gL at amino acid 34. pMN62, pMN117, and pMN102 encode hybrid proteins in which the histidine
hexamer leader sequence (rightward diagonal hatch) is fused to the regions of gL indicated. The hybrid protein encoded by pMN117 has 13 amino
acids, including the 9-amino acid Flu epitope (underlined), added to the carboxyl end.
and stained with crystal violet in 70% ethanol for exami- and most of the HSV-1 strains tested are wild-type
strains, two [HSV-1(F) and HSV-2(G)] of which have beennation by light microscopy. To determine the effects of
mAbs on plaque formation or plaque morphology, Vero passaged only a limited number of times since isolation
from clinical specimens (Ejercito et al., 1968). Mutantscells plated in 24-well dishes were infected with virus at
selected for their Syn phenotype include HSV-1(KOS)804approximately 50 PFU per well. After a 2-hr adsorption
(Little and Schaffer, 1981), HSV-1(HFEM)syn (Baucke andperiod at 377, the viral inoculum was removed and the
cells were incubated for 48 hr in 199V containing dilu-
tions of ascites fluid and 0.5% methyl cellulose. The cells
were then washed, fixed, and stained as above.
Image acquisition and analysis
Autoradiograms of Western blots were scanned using
a Bio-Rad GS-670 Imaging Densitometer. Black and
white negatives obtained by light micrography were
scanned using a Polaroid Sprint scanner. Prints were
produced using Adobe Photoshop and Canvas 3.5 and
printed on a Tektronix Phase IISDX Printer.
RESULTS
Antigenic subtypes of HSV-1 gL
FIG. 2. Reactivity of an anti-gL rabbit antiserum with gL expressed
by various HSV strains. Hep-2 cells were mock-infected or infected atA rabbit antiserum (R88) and mouse mAbs were pro-
10 PFU per cell with one of the virus strains listed below. Cell lysatesduced by immunization with the GST-gL(34–224) hybrid
were prepared at 18 hr after infection and samples from 1.4 1 105 cells
protein depicted in Fig. 1. Analysis of the rabbit antiserum were separated on a 12% SDS–polyacrylamide gel and transferred to
by Western blot revealed the presence of antibodies spe- a nitrocellulose membrane for Western blot analysis. Lane 1, Mock-
infected. Lanes 2–4, HSV-2 strains 333, HG52, G. Lanes 5–18, HSV-1cific for the multiple glycosylated forms of gL found in
strains KOS, KOS(804), SC16(SCgHZ), MP, ANG, HFEM(syn), Patton, F,infected cells (Fig. 2). These antibodies recognized gL
17, Noble, FR, 14-012, Cl101, VR3. The top half of the blot (A) wasencoded by HSV-1(KOS) and by a number of other HSV-
probed with the anti-gH-1 antiserum R83 (1:5000) and the bottom half
1 strains but failed to react with gL produced by two HSV- (B) with the anti-gL-1 antiserum R88 (1:5000). The immunogen used to
1 strains [HSV-1(SC16)SCgHZ and HSV-1(HFEM)syn] and produce R88 was GST-gL(34-224). The positions of molecular weight
standards are indicated.by all three HSV-2 strains tested. All the HSV-2 strains
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FIG. 3. Amino acid sequence comparisons for several HSV-1 forms of gL and HSV-2 gL. Nucleotide sequences were determined for the gL open
reading frames of HSV-1 strains KOS, KOS(804), HFEM(syn), and SC16(SCgHZ) (GenBank Accession No. for KOS gL and KOS(804) gL is U53683;
the Accession No. for HFEM(syn) gL and SC16(SCgHZ) gL is U53684). The amino acid and nucleotide sequences for KOS and KOS(804) gL were
identical so that the lines labeled KOS represent both. The inferred amino acid sequences are compared with the published sequences for HSV-
1(17) gL (McGeoch et al., 1988) and HSV-2(HG52) gL (McGeoch et al., 1991). The asterisks indicate positions where one or more of the HSV-1
strains differ in sequence from HSV-1(17). The HSV-1(17) sequence is underlined at the position of a site for the addition of N-linked carbohydrate.
The downward arrow at position 34 indicates the first gL amino acid present in three of the hybrid proteins depicted in Fig. 1. The arrow at position
169 indicates the first gL amino acid in the C-terminal His-gL hybrid protein (Fig. 1).
Spear, 1979), and HSV-1(MP) (Hoggan and Roizman, HSV-1(KOS) and HSV-1(17). The nucleotide and amino
acid sequences of HSV-1(KOS)804 gL proved to be identi-1959). Strain HSV-1(ANG) is one of the rare Syn strains
isolated directly from clinical material but the method of cal to those of HSV-1(KOS) gL, despite an earlier report
that the Syn mutation of HSV-1(KOS)804 mapped to gLisolation under agar (Munk and Ludwig, 1972) may have
selected for a Syn phenotype (Goodman and Engel, (Little and Schaffer, 1981). A more recent study showed
that the Syn mutation of this strain maps to gK (Roop et1991). Strain HSV-1(SC16)SCgHZ is a gH-negative mu-
tant derived from HSV-1(SC16) (Forrester et al., 1992). al., 1993).
The positions of the amino acid substitutions in theThe parental strains, HSV-1(SC16) and HSV-1(HFEM), as
well as the mutant strains derived therefrom produced a HSV-1 strains that failed to react with the anti-gL antibod-
ies suggested that the epitopes recognized by these anti-form of gL that was not recognized by the antibodies
(data not shown and Fig. 2). Therefore, neither the gH- bodies are in the C-terminal half of HSV-1(KOS) gL. Hy-
brid proteins containing different regions of HSV-1(KOS)negative nor Syn phenotype could account for the lack
of reactivity of the antibodies with the SC16 or HFEM gL, as depicted in Fig. 1, were tested for reactivity with
the antibodies by Western blot (Fig. 4). All five anti-gLforms of gL. Moreover, gL produced by a gH-negative
mutant of HSV-1(KOS) was recognized by the antibodies mAbs (represented by VIII-62 in Fig. 4A) and the rabbit
antiserum raised against the prokaryotic hybrid protein(Novotny and Spear, manuscript in preparation). Results
similar to those shown in Fig. 2, with the same patterns GST-gL(34–224) (Fig. 4B) bound to His-gL(34–224) and
His-gL(168–224) but failed to bind to His-gL(34–169)Flu.of reactivity and lack of reactivity, were obtained also for
all five of the anti-gL mAbs (data not shown). Rabbit antibodies raised against full-length gL produced
by an adenovirus vector (Fig. 4C) and antibodies presentNucleotide sequences were determined for the gL
open reading frames of HSV-1(KOS), HSV-1(KOS)804, in pooled human g-globulin (data not presented) were
similarly reactive with His-gL(34–224) and His-gL(168–HSV-1(HFEM)syn, and HSV-1(SC16)SCgHZ. The inferred
amino acid sequence for HSV-1(KOS) gL was found to 224) but also reacted with His-gL(34–169)Flu. Thus,
there are epitopes recognizable by antibodies in the re-be very similar to that of the published HSV-1(17) gL
sequence (McGeoch et al., 1988), except for two amino gion between amino acids 34 and 169. All of the anti-gL
mAbs and the two rabbit antisera reacted specificallyacid substitutions (P22S and Y109H) in the N-terminal
half of the molecule (Fig. 3). The amino acid sequences with gL in virion extracts (lanes 1 in Figs. 4A–C), whereas
the preimmune rabbit sera were negative (data notfor HSV-1(HFEM)syn and HSV-1(SC16)SCgHZ gL were
identical to each other but differed at six positions in the shown). As expected, only the most mature form of gL
was detected on Western blots of virion proteins,C-terminal half of the protein from the sequences for
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FIG. 4. Localization of gL epitopes by Western blot with His-gL hybrid proteins. Antigens, separated on a 15% SDS–polyacrylamide gel and
transferred to nitrocellulose for Western blotting, were an NP-40 extract of purified HSV-1(KOS) virions (lanes 1) and the purified hybrid proteins
His-gL(34-224) (lanes 2), His-gL(168-224) (lanes 3), and His gL(34-169)Flu (lanes 4). The bound antibodies detected after blotting were from culture
fluids of the anti-gL hybridoma VIII-62 (A) or the anti-FLU hybridoma 12CA5 (D) or from antiserum of rabbit R88 (1:4000) immunized with GST-gL(34-
224) (B) or rabbit R89 (1:1000) immunized with an adenovirus expressing full-length gL (C). The positions of full-length gL and the gL hybrid proteins
are indicated on the right and of proteins used as molecular weight standards, ranging from 6 to 44 kDa, on the left.
whereas multiple mature and immature forms were de- were able to bind to purified HSV-1(KOS) virions (Fig. 6).
Control anti-gB, anti-gD, and anti-gH mAbs also boundtected in infected cell lysates (Fig. 2). In Fig. 4C, the
highest molecular weight bands in each of lanes 1, 2, to the virions as predicted, whereas an anti-gC mAb,
which recognizes HSV-1(HFEM) gC but not HSV-1(KOS)and 4 are believed to be serum or bacterial proteins
recognized by contaminating antibodies in the rabbit an-
tiserum R89.
It can be concluded from the results presented in Fig.
4 that the C-terminal 55-amino acid domain of HSV-
1(KOS) gL, encompassing four of the positions that are
substituted in the SC16 and HFEM strains, displays the
major epitopes recognized by the mAbs and the rabbit
antiserum raised to GST-gL(34–224). One or more of the
four amino acid substitutions in SC16 or HFEM must
eliminate the epitopes recognized by the HSV-1(KOS)-
specific antibodies. Thus, HSV-1 strains fall into at least
two subtypes based on the antigenic determinants pres-
ent in the C-terminal quarter of gL.
Inhibitory activities of the anti-gL antibodies
Each of the five mAbs and two rabbit antisera (both
R88 and R89) were tested for ability to neutralize HSV-
1(KOS) and HSV-1(KOS)804 infectivity. In a standard
plaque reduction assay, neutralizing activity was virtually
undetectable in all cases, in the presence or absence of
complement. The rabbit antisera, even at dilutions as low
as 1:20, failed to achieve 50% reduction in plaque counts.
FIG. 5. Neutralization of various HSV-1 strains by mAbs specific forA couple of the anti-gL mAbs may have very weak neu-
gD, gH, or gL. Samples of the virus strains indicated were incubatedtralizing activity against HSV-1(KOS) and HSV-1(KOS)804,
with dilutions of ascites fluids containing the amounts of mouse IgG
but not appreciably more than against HSV-1(HFEM)syn given for 1 hr at 377 and then aliquots were plated in duplicate on Vero
(Fig. 5), which fails to express gL epitopes that can be cells to quantitate residual infectious units. The ascites fluids contained
the anti-gD mAb III-174 (closed circles), the anti-gH mAb 52S (closedrecognized in Western blots (Fig. 2) or on the surfaces
triangles), or each of the five anti-gL mAbs, each tested at a singleof intact infected cells (see below). It should be noted
high concentration (closed squares). Results are presented as PFU inthat this weak activity required concentrations of mAb
the presence of mAb as a percentage of PFU in the absence of ascites
10- or 100-fold higher than those required for neutraliza- fluid. The results shown were obtained in the absence of rabbit comple-
tion by anti-gD and anti-gH mAbs (Fig. 5). By ELISA it ment. Similar results were obtained in the presence of rabbit comple-
ment.was shown that at least three of the five anti-gL mAbs
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FIG. 6. Binding of mAbs to HSV-1(KOS) virions detected by ELISA. Purified HSV-1(KOS) virions coated onto 96-well plates were incubated with
dilutions of hybridoma culture supernatants containing the amounts of mouse IgG indicated. After washing away unbound antibodies, the enzyme-
linked secondary antibody was applied and substrate added for quantitation of bound horseradish peroxidase. The optical density at 490 nm reflects
the amount of bound antibody. The left panel shows results obtained with the anti-gL mAbs VII-62, VIII-82, VIII-87, VIII-200, and VIII-820. The right
panel shows results obtained with mAbs III-174 (anti-gD), 52S (anti-gH), and II-105 (anti-gB). The mAb II-529 is specific for HSV-1(HFEM) gC, fails
to react with HSV-1(KOS) gC, and served as a negative control. The results presented in both panels were obtained in a single experiment using
a single batch of purified virus to coat the plates and a single set of reagents.
gC, failed to bind. Immunoprecipitation experiments were on HSV-1-induced cell fusion, Vero cells were infected
with either HSV-1(KOS)804 or HSV-1(HFEM)syn at 20 PFUalso done to determine whether anti-gL mAbs could bind
to intact virions. Figure 7 shows that both anti-gL and per cell and, after allowing time for virus adsorption and
anti-gB mAbs precipitated HSV-1(KOS) virions, whereas penetration in the absence of antibodies, the infected
only the anti-gB mAb precipitated HSV-1(HVEM) virions. cells were incubated in medium containing a range of
Thus, binding of anti-gL mAbs to HSV-1(KOS) virions concentrations of various mAbs. The results presented
could be demonstrated but was not associated with ef- in Fig. 8 and Table 1 show that all five of the anti-gL
fective neutralization of virion infectivity in the absence mAbs inhibited cell fusion induced by HSV-1(KOS)804,
(Fig. 5) or presence (data not shown) of complement. but not by HSV-1(HFEM)syn. For HSV-1(KOS)804, com-
To determine whether the anti-gL mAbs had any effect plete inhibition of fusion was achieved with lower con-
centrations of the anti-gL mAbs than other mAbs (anti-
gD and anti-gH) previously shown to inhibit HSV-induced
cell fusion (Noble et al., 1983; Minson et al., 1986; Gom-
pels and Minson, 1986). Cell fusion induced by HSV-
1(HFEM)syn could be inhibited by the anti-gD and anti-
gH mAbs as expected. The anti-gC and anti-gE mAbs
failed to inhibit fusion induced by either virus, also as
expected (Noble et al., 1983). In fact, we noted that fusion
activity was reproducibly greater in the presence of anti-
gC mAbs. The anti-gB mAb had only minimal activity in
inhibiting fusion induced by HSV-1(KOS)804. Other anti-
FIG. 7. Immunoprecipitation of intact HSV-1(KOS) virions by an anti- gB mAbs have been shown to inhibit cell fusion (Navarro
gL mAb. Samples of purified HSV-1(KOS) or HSV-1(HFEM) virions were et al., 1992). Representative results obtained with anti-
mixed with ascites fluids containing the anti-gL mAb VIII-87 (lanes 2) gL VIII-200 (Figs. 8B and 8F), anti-gH 52S (Figs. 8C and
or the anti-gB mAb II-105 (lanes 3). After 3 hr on ice, immune complexes
8G), and anti-gC VII-13-7 (Figs. 8D and 8H) are shownwere bound to protein A agarose and, after thorough washing of the
for HSV-1(KOS)804-infected and HSV-1(HFEM)syn-in-agarose beads, solubilized for SDS–PAGE and Western blotting with
a rabbit antiserum (anti-NC-1) specific for the major capsid protein VP5. fected Vero cells, respectively.
Control samples received no mAb (lanes 1) or no virus or mAb (C) but To determine whether the anti-gL mAbs could inhibit
were otherwise treated as the virus-mAb mixtures. The lane labeled V
plaque formation or convert syncytial plaques to a non-was loaded with proteins extracted from about 1.51 108 PFU of purified
syncytial phenotype, Vero cells were infected with HSV-HSV-1(KOS). The positions of molecular weight markers are indicated
on the left. 1(KOS), HSV-1(KOS)804, or HSV-1(HFEM)syn and, after
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FIG. 8. Inhibition of HSV-1(KOS)804-induced cell fusion by anti-gL mAbs. Vero cells were mock-infected (inset in A) or infected with HSV-1(KOS)804
(top panels) or HSV-1(HFEM)syn (bottom panels) at 20 PFU per cell and then overlaid with 199V containing 0.5% methyl cellulose and no antibody
(A and E), the anti-gL mAb VIII-200 at 40 mg/ml (B and F), the anti-gH mAb 52S at 40 mg/ml (C and G), or the anti-gC mAb VII-13-7 at 60 mg/ml (D
and H). At 18 hr after infection, the monolayers were fixed, stained, and photographed.
virus adsorption, incubated with anti-gL, anti-gH, or anti- gL VIII-87). There was no effect of the anti-gL mAbs on
plaques formed by HSV-1(HFEM)syn (Fig. 9H), as ex-gD mAbs. The anti-gL mAbs reduced the sizes of both
HSV-1(KOS) and HSV-1(KOS)804 plaques and changed pected based on the results presented in Figs. 2 and 8.
The anti-gD (Figs. 9C, 9F, and 9I) and anti-gH (not shown)the morphology of HSV-1(KOS)804 plaques from syncytial
to nonsyncytial (as illustrated in Figs. 9B and 9E, for anti- mAbs reduced plaque size even more dramatically than
TABLE 1
Inhibition of HSV-1-Induced Cell Fusion by Monoclonal Antibodies
Monoclonal antibody HSV-1(KOS)804 HSV-1(HFEM)syn
Inhibitory Inhibitory
IgG dosec Fusion dosec Fusion
Specificity Immunogena Name subisotypeb (mg/ml) inhibited (mg/ml) inhibited
gB HFEM II-105 2a 200 Yes 200 No
gC KOS VII-13-7 2a 314 No 314 No
gD G III-114 2b 140 Yes 6 Yes
gD G III-174 2a 90 Yes 18 Yes
gE G III-252 NDd 140 No 140 No
gH 14-012 52S 2a 160 Yes 32 Yes
gL KOS VIII-62 3 12 Yes 300 No
gL KOS VIII-82 2b 42 Yes 1060 No
gL KOS VIII-87 2b 10 Yes 1200 No
gL KOS VIII-200 2a 64 Yes 1600 No
gL KOS VIII-820 2a 35 Yes 800 No
a Virus strain used to prepare antigen for immunization of mice to obtain B cells for hybridoma production. All strains are HSV-1 except G, which
is HSV-2.
b Subisotypes were reported by Para et al. (1985) for II-105, III-114, and III-174 and by Showalter et al. (1981) for 52S. All other subisotypes given
were determined for this study by use of a subisotyping ELISA kit from Hyclone Laboratories, Inc.
c The concentrations of antibody required to completely inhibit the fusion of Vero cells infected at a multiplicity of 20 PFU/cell.
d Not determined.
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FIG. 9. Inhibition of plaque size and Syn phenotype by anti-gL mAbs specific for HSV-1(KOS) strains. Vero cells were infected with HSV-1(KOS)
(top panels), HSV-1(KOS)804 (middle panels), or HSV-1(HFEM)syn (bottom panels) and overlaid with 199V containing 0.5% methyl cellulose and no
antibody (A, D, and G), the anti-gL mAb VIII-87 at 60 mg/ml (B, E, and H), or the anti-gD mAb III-174 at 25 mg/ml (C, F, and I). At 48 hr after infection
the monolayers were fixed, stained, and photographed.
did the anti-gL mAbs, for all three virus strains, and 1 strains but not others, reacted preferentially with epi-
topes localized between amino acids 168 and 224, andchanged the morphology from syncytial to nonsyncytial,
as previously reported for other HSV-1 strains (Gompels inhibited cell fusion induced by some Syn strains but not
others. The C-terminal quarter of gL also exhibits theand Minson, 1986; Minson et al., 1986). The extreme
reduction in plaque size was probably due to the com- greatest divergence in amino acid sequence between
HSV-1 and HSV-2 forms of gL. Presumably the aminobined inhibitory effects of the anti-gD and anti-gH mAbs
acid substitutions in different forms of HSV-1 gL do noton virion infectivity as well as on cell fusion.
affect substantially the oligomerization of gL with gH,
consistent with our observation that the C-terminal do-DISCUSSION
main is dispensible for this oligomerization (Novotny and
Important epitopes were localized to the C-terminal Spear, manuscript in preparation). Other activities of gL,
quarter of gL for antibodies raised against different pro- such as participation in the induction of cell fusion, may
karyotic and eukaryotic forms of HSV-1(KOS) gL in mice be more dependent on the C-terminal domain. Certainly,
or rabbits or for antibodies found in pooled human g- antibodies specific for this domain were found to be po-
globulin. This domain of gL was found to differ in amino tent inhibitors of cell fusion. The possibility exists that
acid sequence and epitope conformation among HSV-1 antibodies may help to drive the antigenic variation in
strains, defining at least two antigenic subtypes of HSV- this domain of gL.
1 gL. Thus, antibodies raised against GST-gL(34–224) The entry of HSV into cells and HSV-induced cell fusion
are both dependent on virus-induced membrane fusion.reacted in Western blots with gL produced by some HSV-
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The finding that anti-gL mAbs were very effective at inhib- in these molecular interactions required for cell fusion
or influences the functional conformations of gL or inter-iting cell fusion, but had little if any effect on viral entry,
sets gL apart from gB, gD, and gH, although all four HSV- actions of gL with gH or other components. The variability
in amino acid sequence of this domain must be compati-1 glycoproteins are required for both processes. Antibod-
ies raised against HSV-1 gB, gD, or gH can inhibit viral ble with these functional interactions.
entry, cell fusion or both. Most mAbs with one activity
also exhibit the other, to a greater or lesser degree. ACKNOWLEDGMENTS
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